Castle Creek Biosciences

Cell and Gene Therapy Company

Exton, United States · $167.8M raised

Business Model
B2B
Total Funding
$167.8M
Last Round
$112.8M Series DMay 2022
Rounds
4

About

Castle Creek Biosciences is a late-stage cell and gene therapy company developing re-dosable gene therapies for severe genetic skin diseases. Its lead program, D-Fi, is in a registrational Phase 3 trial for dystrophic epidermolysis bullosa (DEB). A portfolio company of Paragon Biosciences, it is headquartered in Exton, Pennsylvania.

Summary

Castle Creek Biosciences is a Biotech company based in Exton, United States. It has raised $167.8M in total across 4 rounds, most recently a $112.8M Series D round in May 2022. Investors include Paragon Biosciences, Ligand Pharmaceuticals and Valor Equity Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Debt FinancingDebt FinancingFeb 2025
$75.0M

Sign up to see all 5 rounds

Series A through Debt Financing — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Castle Creek Biosciences on Indexed.vc
<a href="https://indexed.vc/companies/castle-creek-biosciences"><img src="https://indexed.vc/api/badge/company/castle-creek-biosciences" alt="Castle Creek Biosciences on Indexed.vc" width="260" height="76" /></a>